Tempest Therapeutics, Inc. (TPST) Earnings History
Annual and quarterly earnings data from 2012 to 2024
Loading earnings history...
TPST EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TPST Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export TPST earnings history in CSV or JSON format
Free sign-in required to download data
Tempest Therapeutics, Inc. (TPST) Earnings Overview
As of May 8, 2026, Tempest Therapeutics, Inc. (TPST) reported trailing twelve-month net income of -$36M, reflecting +21.5% year-over-year growth. The company earned $-8.12 per diluted share over the past four quarters.
Looking at the long-term picture, TPST's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2012.
Tempest Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), AGEN ($115,000 net income, 0.1% margin), AGIO (-$423M net income, -764.0% margin), TPST has comparable earnings metrics. Compare TPST vs IMVT →
TPST Earnings vs Peers
Earnings metrics vs comparable public companies
TPST Historical Earnings Data (2012–2024)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$42M | -41.9% | -$42M | $-1.50 | - | - |
| 2023 | -$29M | +17.4% | -$29M | $-1.91 | - | - |
| 2022 | -$36M | -26.2% | -$35M | $-3.18 | - | - |
| 2021 | -$28M | -48.0% | -$27M | $-7.80 | - | - |
| 2020 | -$19M | +57.1% | -$19M | $-612.56 | - | - |
| 2019 | -$45M | -63.9% | -$45M | $-48.77 | - | - |
| 2018 | -$27M | +67.8% | -$23M | $-263.65 | - | - |
| 2017 | -$85M | -2.8% | -$20M | $-72406.33 | -28670.5% | -6943.1% |
| 2016 | -$82M | -12.3% | -$81M | $-575.73 | -12597.2% | -12406.1% |
| 2015 | -$73M | -47.9% | -$72M | $-608.25 | -26432.9% | -25992.4% |
See TPST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TPST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TPST vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTPST — Frequently Asked Questions
Quick answers to the most common questions about buying TPST stock.
Is TPST growing earnings?
TPST EPS is $-8.12, with earnings growth accelerating to +21.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-36M.
What are TPST's profit margins?
Tempest Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are TPST's earnings?
TPST earnings data spans 2012-2024. The accelerating earnings trend is +21.5% YoY. Historical data enables comparison across business cycles.